Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.

Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial. Gynecol Oncol. 2022 02; 164(2):278-287.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Benzimidazoles
Carboplatin
Drug Administration Schedule
Female
Genes, BRCA1
Genes, BRCA2
Germ-Line Mutation
Hereditary Breast and Ovarian Cancer Syndrome
Humans
Induction Chemotherapy
Maintenance Chemotherapy
Middle Aged
Neoplasms, Cystic, Mucinous, and Serous
Ovarian Neoplasms
Paclitaxel
Poly(ADP-ribose) Polymerase Inhibitors
Young Adult

authors with profiles

Gini Fleming